von Herrath M G, Korsgren O, Atkinson M A
Type 1 Diabetes Center, La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA.
Novo Nordisk Diabetes Research and Development Center, Seattle, WA, USA.
Clin Exp Immunol. 2016 Jan;183(1):1-7. doi: 10.1111/cei.12656. Epub 2015 Jul 24.
Type 1 diabetes (T1D) is one of the most common and severe chronic diseases affecting both children and adults. The aetiology of the disease remains unknown, and thus far no 'true' cure for those affected is available. Indeed, exogenous insulin replacement therapy to manage glucose metabolism to the best degree possible remains the current standard of care. However, despite a recent array of truly impressive improvements designed to enhance disease management (e.g. insulin analogues, continuous glucose monitoring, insulin pumps), it is still difficult for the vast majority of patients to reach recommended target HbA1C levels (< 7.0%). As a result of suboptimal disease management, far too many patients with T1D have an increased risk for disease-associated complications such as nephropathy, neuropathy and retinopathy, as well as hypoglycaemia. New treatment modalities are therefore needed urgently to bring a 'true' cure (disease prevention/disease reversal) to patients with T1D. Here we consider issues that collectively pose a major stumbling block in T1D research with respect to identifying a means to prevent and/or cure the disease. We begin this Perspective by discussing new insights emanating from studies of the pancreas in human T1D; findings which may, at least in part, explain why previous interventions seeking disease prevention/reversal have yielded insufficient benefit. We then turn to suggestions that could optimise the outcome of future clinical trials. Finally, we direct attention to recommendations for the global T1D research community; messages we deem to have the potential to improve our chances of finding the elusive T1D 'cure'.
1型糖尿病(T1D)是影响儿童和成人的最常见、最严重的慢性病之一。该疾病的病因尚不清楚,迄今为止,还没有针对患者的“真正”治愈方法。事实上,通过外源性胰岛素替代疗法尽可能最佳地管理葡萄糖代谢仍然是当前的标准治疗方法。然而,尽管最近有一系列旨在加强疾病管理的真正令人印象深刻的改进措施(如胰岛素类似物、持续葡萄糖监测、胰岛素泵),但绝大多数患者仍难以达到推荐的糖化血红蛋白(HbA1C)目标水平(<7.0%)。由于疾病管理欠佳,太多T1D患者发生肾病、神经病变和视网膜病变等与疾病相关并发症以及低血糖的风险增加。因此,迫切需要新的治疗方法,为T1D患者带来“真正”的治愈方法(疾病预防/疾病逆转)。在此,我们探讨了在T1D研究中共同构成识别预防和/或治愈该疾病方法的主要绊脚石的问题。我们从讨论人类T1D胰腺研究产生的新见解开始这一观点阐述;这些发现至少可以部分解释为什么以前寻求疾病预防/逆转的干预措施带来的益处不足。然后,我们转向可以优化未来临床试验结果的建议。最后,我们将注意力转向对全球T1D研究界的建议;我们认为这些信息有可能提高我们找到难以捉摸的T1D“治愈方法”的机会。